非生物人工肝治疗慢性重型肝炎的临床应用

目的评价非生物人工肝治疗慢性重型肝炎的安全性及早、中、晚期的临床应用效果.方法对132例早、中、晚期慢性重型肝炎患者在综合治疗基础上给予非生物人工肝支持治疗,观察非生物人工肝治疗前后肝功能、肾功能、凝血酶原活动度(PTa)、血常规、临床症状、血氨及不同时期存活率的变化.结果 132例慢性重型肝炎患者进行非生物人工肝治疗后,肝功能检测血清总胆红素(TB)及谷丙转氨酶(ALT)下降,PTa上升(P<.01);临床症状明显改善,不良反应轻,治疗慢性重型肝炎早、中、晚期的存活率分别为90.0%、53.3%、14.9%.结论非生物人工肝治疗慢性重型肝炎患者副作用小,对慢性重型肝炎早、中期有较好的支持作用.

Clinical application of non-bioartificial liver to patients with chronic severe hepatitis

Objective To evaluate the therapeutic efficacy and safety of non-bioartificial liver in treating the patients with chronic severe hepatitis at early, middle and late stage. Methods A total of 132 patients with chronic severe hepatitis received treatment of non-bioartificial liver. Before and after the therapy, liver function, renal function, blood routine test, prothrombin activity (PTa), blood amine were analyzed. Symptoms and signs of all patients were observed closely. The survival rates of patients underwent non-bioartificial liver treatment were investigated. Results After the treatment of non-bioartificial liver, the symptoms and manifestation of patients improved. Serum total bilirubin (TB), alanine amino-transferase (ALT) and blood amine decreased. PTa increased significantly (P<0.01). The side effects were very limited. The survival rates of patients with chronic severe hepatitis at early, middle and late stage were 90.0%, 50.3%, 14.9%, respectively. Conclusion The non-bioartificial liver is an effective means for chronic severe hepatitis, especially at early stage and middle stage.